Search - tctmd.com

Displaying 1 - 20 of 22

Sort: Relevancy | Date

Presentation TCT 2017

Flash Debate: Surgery Remains the First Option in All Operable Patients With Bicuspid Aortic Stenosis!

Presenter: Gilles Dreyfus, Sanjay Kaul, Alfredo Trento

November 01, 2017

Presentation TCT 2017

Flash Debate: Enough Evidence Is Present to Justify TAVR in Select Patients With Bicuspid Aortic Stenosis!

Presenter: Gilles Dreyfus, Sanjay Kaul, John G. Webb

November 01, 2017

Presentation TCT 2017

Flash Debate: Surveillance and Prophylactic Treatment of Asymptomatic TAVR Thrombosis Is Not Currently Warranted!

Presenter: Gilles Dreyfus, Sanjay Kaul, Hendrik Treede

November 01, 2017

Presentation TCT 2017

Flash Debate: Valve Thrombosis After TAVR Is a Serious Concern That Deserves Detection and Management!

Presenter: Gilles Dreyfus, Sanjay Kaul, Raj Makkar

November 01, 2017

Presentation TCT 2017

Flash Debate: Based on Clinical Studies, Embolic Protection Devices Should Infrequently Be Used During TAVR

Presenter: Gilles Dreyfus, Sanjay Kaul, Duane S. Pinto

November 01, 2017

Presentation TCT 2017

Flash Debate: The Evidence and Clinical Need Justifies the Widespread Use of Embolic Protection During TAVR

Presenter: Gilles Dreyfus, Sanjay Kaul, Samir R. Kapadia

November 01, 2017

Presentation TCT 2017

Flash Debate: Bioresorbable Scaffolds Are Appropriate for Clinical Use in Suitable Patients With Optimal Technique!

Presenter: Sanjay Kaul, Tullio Palmerini, Robert-Jan van Geuns

November 01, 2017

Presentation TCT 2017

Flash Debate: Bioresorbable Scaffolds Should Rarely be Used Outside of Carefully Controlled Research Studies!

Presenter: Sanjay Kaul, Tullio Palmerini, Robert A. Byrne

November 01, 2017

Presentation TCT 2017

Flash Debate: If Anything, Guideline Recommendations for PCI in Low-to-Intermediate Risk Left Main Disease Should be Downgraded Based on EXCEL and NOBLE!

Presenter: Sanjay Kaul, Tullio Palmerini, Jacek Legutko

November 01, 2017

Presentation TCT 2017

Flash Debate: Guideline Recommendations for PCI in Low-to-Intermediate Risk Left Main Disease Should Be Upgraded to Class I Based on EXCEL and NOBLE!

Presenter: Sanjay Kaul, Tullio Palmerini, Evald H. Christiansen

November 01, 2017

Presentation TCT 2017

Flash Debate: Registry Data and Personal Experiences Are Strong Enough to Justify Frequent Use of IMPELLA in High-Risk PCI and Cardiogenic Shock!

Presenter: Sanjay Kaul, Tullio Palmerini, Dimitri Karmpaliotis

November 01, 2017

Presentation TCT 2017

Flash Debate: There Is Insufficient Evidence From Randomized Trials to Justify Frequent Use of Impella in High-Risk PCI and Cardiogenic Shock!

Presenter: Sanjay Kaul, Tullio Palmerini, Holger Thiele

November 01, 2017

Presentation TCT 2017

Flash Debate: FFR/iFR in ACS Patients With MVD There is Little Credible Evidence on Which to Base Any Recommendations!

Presenter: Sanjay Kaul, Tullio Palmerini, Francesco Saia

November 01, 2017

Presentation TCT 2017

Flash Debate: FFR/iFR in ACS Patients With MVD - Based on the Evidence the Guidelines are Justified and Should Be Even Stronger!

Presenter: Sanjay Kaul, Tullio Palmerini, Tim P. van de Hoef

November 01, 2017

Presentation TCT 2017

Perspectives on the Feasibiity and Trustworthiness of Large, Simple Trials: From TASTE to ADAPTABLE

Presenter: Robert A. Harrington, Sanjay Kaul, Schuyler Jones

October 30, 2017

Presentation TCT 2017

Risk Score Development, Validation, Precision, Discrimination, and Utility

Presenter: Robert A. Harrington, Sanjay Kaul, Davide Capodanno

October 30, 2017

Presentation TCT 2017

Do Patients Really Do Better When Their Cardiologists Are Away at Conferences? Embedding Controls in Observational Studies

Presenter: Robert A. Harrington, Sanjay Kaul, Robert W. Yeh

October 30, 2017

Presentation TCT 2017

Assessment of the Quality and Reliability of Meta-analysis (Summary Level, Network, and Individual Patient Data-Based)

Presenter: Robert A. Harrington, Sanjay Kaul, Giuseppe Biondi-Zoccai

October 30, 2017

Presentation TCT 2017

Natures Randomized Trials: Natural Experiments, Instrumental Variables, and Mendelian Randomization (Strengths and Limitations)

Presenter: Robert A. Harrington, Sanjay Kaul, Robert W. Yeh

October 30, 2017

Presentation TCT 2017

The Worst Misinterpretations Ive Seen in Observational Research Studies: How to Spot Them, How to Avoid Them

Presenter: Robert A. Harrington, Sanjay Kaul

October 30, 2017

Advertisement

Flash Debate: Surgery Remains the First Option in All Operable Patients With Bicuspid Aortic Stenosis!

Flash Debate: Enough Evidence Is Present to Justify TAVR in Select Patients With Bicuspid Aortic Stenosis!

Flash Debate: Surveillance and Prophylactic Treatment of Asymptomatic TAVR Thrombosis Is Not Currently Warranted!

Flash Debate: Valve Thrombosis After TAVR Is a Serious Concern That Deserves Detection and Management!

Flash Debate: Based on Clinical Studies, Embolic Protection Devices Should Infrequently Be Used During TAVR

Flash Debate: The Evidence and Clinical Need Justifies the Widespread Use of Embolic Protection During TAVR

Flash Debate: Bioresorbable Scaffolds Are Appropriate for Clinical Use in Suitable Patients With Optimal Technique!

Flash Debate: Bioresorbable Scaffolds Should Rarely be Used Outside of Carefully Controlled Research Studies!

Flash Debate: If Anything, Guideline Recommendations for PCI in Low-to-Intermediate Risk Left Main Disease Should be Downgraded Based on EXCEL and NOBLE!

Flash Debate: Guideline Recommendations for PCI in Low-to-Intermediate Risk Left Main Disease Should Be Upgraded to Class I Based on EXCEL and NOBLE!

Flash Debate: Registry Data and Personal Experiences Are Strong Enough to Justify Frequent Use of IMPELLA in High-Risk PCI and Cardiogenic Shock!

Flash Debate: There Is Insufficient Evidence From Randomized Trials to Justify Frequent Use of Impella in High-Risk PCI and Cardiogenic Shock!

Flash Debate: FFR/iFR in ACS Patients With MVD There is Little Credible Evidence on Which to Base Any Recommendations!

Flash Debate: FFR/iFR in ACS Patients With MVD - Based on the Evidence the Guidelines are Justified and Should Be Even Stronger!

Perspectives on the Feasibiity and Trustworthiness of Large, Simple Trials: From TASTE to ADAPTABLE

Risk Score Development, Validation, Precision, Discrimination, and Utility

Do Patients Really Do Better When Their Cardiologists Are Away at Conferences? Embedding Controls in Observational Studies

Assessment of the Quality and Reliability of Meta-analysis (Summary Level, Network, and Individual Patient Data-Based)

Natures Randomized Trials: Natural Experiments, Instrumental Variables, and Mendelian Randomization (Strengths and Limitations)

The Worst Misinterpretations Ive Seen in Observational Research Studies: How to Spot Them, How to Avoid Them

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content